December 2015
ActiveSite awarded United States Patent 9,206,123, Prodrugs of Inhibitors of Plasma Kallikrein.
April 2014
ActiveSite awarded United States Patent 8,691,861, Prodrugs of Inhibitors of Plasma Kallikrein.
February 2014
ActiveSite and Joslin Diabetes Center awarded United States Patent 8,658,685, Methods for Treatment of Kallikrein-Related Disorders.
December 2013
ActiveSite awarded United States Patent 8,609,866, Prodrugs of Inhibitors of Plasma Kallikrein.
September 2012
ActiveSite awarded United States Patent 8,258,170, Inhibitors of Plasma Kallikrein.
May 2012
ActiveSite Pharmaceuticals’ Announces the Award of a Competitively Renewed Phase II SBIR Grant From the National Institutes of Health, Press Release.
July 2011
ActiveSite awarded United States Patent 7,977,380, Inhibitors of Plasma Kallikrein.
March 2011
ActiveSite Pharmaceuticals' Small Molecule Protease Inhibitor Blocks Retinal Blood Vessel Damage in Rodent Model of Diabetes,
Press Release.
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats, Diabetes, 60, 1590-98 (2011)
February 2011
Hyperglycemia-induced Cerebral Hematoma Expansion is Mediated by Plasma Kallikrein, Nature Medicine, 17, pp 206-210 (2011).
November 2010
ActiveSite awarded Qualifying Therapeutic Discovery Project Grant for Preclinical & Early Clinical Development of a NCE Targeting Diabetic Macular Edema.
December 2009
ActiveSite awarded United States Patent 7,625,944, Inhibitors of Plasma Kallikrein.
July 2009
ActiveSite awarded SBIR Phase II Grant from the National Eye Institute, Novel Orally-active Plasma Kallikrein Inhibitors for Diabetic Retinopathy.
January 2009
Researchers Describe Protease Inhibitor That May Aid in Diabetic Retinopathy Treatment, Press Release.
Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-stimulated Retinal Vascular Permeability, Hypertension, 53, pp 175-81 (2009).
September 2007
ActiveSite awarded SBIR Phase I Grant from the National Heart Lung and Blood Institute, Novel Anti-thrombotic Approach for Treatment of Myocardial Infarction.
|